Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.

Peter W. Janes(Olivia Newton-John Cancer Wellness & Research Centre), Robert L. Sutherland(Garvan Institute of Medical Research), Anna DeFazio(The University of Sydney), Roger J. Daly(Discovery Institute)
PubMed
December 1, 1994
Cited by 200

Related Papers

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary
|The Journal of Pathology|2010|836
Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary
|New England Journal of Medicine|2009|775
The SH2/SH3 domain‐containing protein GRB2 interacts with tyrosine‐phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.
|The EMBO Journal|1993|707